Archean Chemical Industries (ACI) Share Analysis: Earnings, Latest Results, Shareholding Pattern & the Road Ahead
Every bull market throws up companies that promise to become something entirely different from what they are today. Archean Chemical Industries Limited (ACI) is one of those fascinating bets. On paper, it is a specialty marine chemicals company making bromine, industrial salt and sulphate of potash from the brine reserves of the Rann of Kutch. Dig deeper, and you find it is quietly building India's first approved silicon carbide (SiC) semiconductor fab in Odisha, an 18% stake in a UK-based zinc-bromide battery venture, and a fast-maturing bromine derivatives business. The stock has been beaten down over the past year, but the Q1 FY27 results have started showing green shoots. Is this a multi-bagger in the making or an expensive chemical stock with too many irons in the fire? Let us break it down completely.
What's Inside This Article
1. Company Overview – What Does ACI Actually Do?
Archean Chemical Industries is a Chennai-headquartered, specialty marine chemicals manufacturer with its integrated production facility at Hajipir, on the northern edge of the Rann of Kutch brine fields in Gujarat. The facility, along with its surrounding salt fields and brine reservoirs, spans roughly 240 square kilometres – making it one of the largest single-location salt works anywhere in the world. The company owns captive port infrastructure (Jakhau jetty) and ships through Mundra and Kandla ports.
Think of ACI as a "brine refinery". Sea brine is evaporated, and from that single resource the company extracts three products:
- Bromine (the profit engine): Installed capacity of 42,500 tonnes per annum (28,500 TPA merchant + 14,000 TPA captive). ACI is the largest exporter of bromine from India and enjoys a leadership position in elemental bromine merchant sales globally. Bromine goes into flame retardants, pharma APIs, agrochemicals, water treatment, oilfield chemicals and now, energy storage.
- Industrial salt (the volume engine): A massive 75 lakh tonnes per annum capacity – and it is a 100% export-oriented business serving chlor-alkali producers in Japan, South Korea, East Asia and the Middle East.
- Sulphate of Potash (SOP – the optional kicker): 1,32,000 TPA capacity. ACI is the only manufacturer of natural sea-brine-based SOP in India, a country that otherwise imports this chloride-free fertiliser.
Beyond these three legacy lines, ACI has layered on four new businesses: bromine derivatives (Acume Chemicals, Jhagadia, Gujarat), oilfield/mud chemicals (Idealis Mudchemie, acquired out of an NCLT auction for about ₹77 crore), silicon carbide power semiconductors (SiCSem, Odisha), and zinc-bromide batteries (strategic stake in Offgrid Energy Labs, UK).
2. The Journey So Far – Past Performance
ACI's story has three clear chapters. Chapter one (2013–2022): build-out. Salt operations began in 2013, bromine in 2014, SOP in 2015. Japanese trading house Sojitz came in as a strategic investor in 2011, and by FY22 the company was generating ₹1,130 crore of revenue.
Chapter two (FY23–FY24): the golden era. Global bromine prices spiked, and ACI printed stunning numbers – FY23 revenue of ₹1,441 crore with a 44% operating margin and ₹383 crore net profit. The company went public in November 2022 at ₹407 per share (a ₹1,462 crore IPO), used ₹805 crore of fresh money to become almost debt-free, and listed at around ₹458.
Chapter three (FY25–FY26): the reality check. Bromine prices corrected sharply on Chinese oversupply and soft demand, industrial salt pricing weakened, a cyclone wiped out ~4.7 lakh tonnes of salt inventory (a ₹40 crore one-off loss in FY25), and the new ventures were still bleeding money. Result: PAT fell from ₹383 crore in FY23 to just ₹105 crore in FY26. The stock, which touched ₹727 in August 2025, slid to a 52-week low of ₹483 by December 2025 and has broadly remained in the ₹490–580 band since.
| Consolidated (₹ Cr) | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue from operations | 1,441 | 1,330 | 1,041 | 1,081 |
| Operating profit (EBITDA) | 634 | 463 | 315 | 239 |
| EBITDA margin | 44% | 35% | 30% | 22% |
| Net profit (PAT) | 383 | 319 | 162 | 105 |
| Earnings per share (₹) | 31.1 | 25.9 | 13.1 | 8.66 |
| ROCE | ~45% | ~25% | ~13% | ~7.4% |
That table tells you everything about why the stock de-rated. Three-year profit CAGR is deeply negative, and return ratios have compressed from spectacular to ordinary as capex on new ventures rose and core margins cooled. Balance-sheet-wise, the company still carries healthy reserves (₹1,910 crore as of March 2026), but borrowings have climbed back to about ₹466 crore to fund the semiconductor and battery bets. Dividend has been maintained – ₹2.50 per share for FY26 (roughly 29% payout, ~0.5% yield at current price).
3. Latest Quarterly Result – Q1 FY27 (June 2026 Quarter)
Declared on 30 July 2026, this was arguably ACI's most important result in six quarters – the first clear evidence that the down-cycle is bottoming out.
| Consolidated (₹ Cr) | Q1 FY27 (Jun '26) | Q4 FY26 (Mar '26) | Q1 FY26 (Jun '25) | YoY Change |
|---|---|---|---|---|
| Revenue | 327 | 301 | 292 | +11.9% |
| EBITDA | 73 | 49 | 86 | –15.6% |
| EBITDA margin | ~21% | ~15% | ~27% | –600 bps |
| Net profit (PAT) | 30.4 | 13.4 | 40.2 | –23.7% |
| EPS (₹) | 2.48 | 1.13 | 3.25 | down |
Read the headline and the direction together: revenue hit a record quarterly high of ₹327 crore (highest-ever quarterly sales for the company), and profit more than doubled sequentially from the miserable March quarter. But versus last year, profitability is still lower. Here is what actually happened inside the business:
- Bromine roared back: Segment revenue jumped 58% YoY to ₹133 crore on volumes of 4,175 tonnes (a five-quarter high) and realisations up ~50% YoY to roughly ₹300 per kg. Demand from flame retardants, oilfield chemicals and energy storage stayed firm, and management expects realisations to hold near this level.
- Industrial salt struggled: Revenue fell 12% YoY to ₹171 crore as volumes dropped to 9.82 lakh tonnes. The culprits were purely operational – Gujarat highway construction lengthened truck routes by 50–100% (the Hajipir–Jakhau haul nearly doubled to 500+ km), diesel prices ran ~60% higher YoY during April–June, sea freight rose 30–35% due to the West Asia conflict, and a key Middle East salt customer stayed on hold. Crucially, salt pricing has stabilised after falling through FY26.
- Bromine derivatives turned EBITDA-positive for the first time: Acume Chemicals grew revenue 28% YoY to ~₹30 crore and posted positive EBITDA of ₹1.9 crore (versus a ₹2.7 crore loss a year ago) on ~40% capacity utilisation. Pharma-grade variants and organic bromides are leading the mix.
- SOP is coming back to life: Revenue of ₹11.3 crore in the quarter – against just ₹3.5 crore in ALL of FY26 – on 1,952 tonnes sold at ~₹58,000/tonne. The re-engineered manufacturing process cleared Phase-1 trials in June 2026; Phase-2 trials are due by December 2026.
- New-age ventures in investment mode: The semiconductor venture (Neun/SiCSem) and oilfield chemicals arm (Idealis) together remain loss-making at the EBITDA level, dragging consolidated profit about ₹10 crore below standalone profit.
4. Shareholding Pattern – Who Owns ACI?
The shareholding of ACI is actually one of its better features: a stable promoter, rising foreign ownership, and strong domestic institutional backing.
| Shareholder Category | Mar 2024 | Mar 2025 | Jun 2026 |
|---|---|---|---|
| Promoters & Promoter Group | 53.46% | 53.44% | 53.43% |
| Foreign Institutional Investors (FIIs) | 5.86% | 10.93% | 11.00% |
| Domestic Institutional Investors (DIIs) | 27.13% | 23.17% | 24.18% |
| – of which Mutual Funds | – | – | 16.15% |
| Public & Others | 13.54% | 12.44% | 11.40% |
Institutions (FIIs + DIIs) together hold roughly 35% of the company – a strong vote of professional confidence for a smallcap. FII holding has almost doubled since FY24. Retail participation, interestingly, has thinned – the shareholder count has come down from about 1.07 lakh in March 2024 to around 67,000 now, suggesting weak hands have exited the stock during the down-cycle.
5. Present – Where the Stock Stands Right Now
As of late August 2026, ACI trades around ₹498, valuing the company at roughly ₹6,100 crore. The stock is down about 24–26% over the past year, has a 52-week range of ₹483–727.6, and trades at a trailing P/E of about 63x with a price-to-book of ~3.2x. On current earnings, that is expensive – no two ways about it. The bull case rests entirely on the earnings recovery that Q1 FY27 has begun to signal.
| Valuation Snapshot (Aug 2026) | ACI | Pidilite | Navin Fluorine | Deepak Nitrite | Aarti Inds. |
|---|---|---|---|---|---|
| P/E (trailing) | ~63x | ~63x | ~53x | ~30x | ~37x |
| ROCE | 7.4% | 31% | 21% | 11% | 7% |
The Street remains cautiously constructive. Post the Q1 print, a large domestic broker reiterated a Buy with a target of ₹640 (valuing the company at 16x FY28E EV/EBITDA), while flagging SiCSem execution as the key re-rating catalyst. Broad analyst consensus targets cluster around the ₹590–600 mark – implying roughly 20% upside from current levels, though estimates vary widely because FY27–28 earnings are unusually hard to model. It is also worth noting that ACI is a small-cap index constituent (part of the Nifty Smallcap 500 and Nifty Microcap 250 baskets) – so index flows matter, and the stock is not yet in the big league of index heavyweights.
6. Future – Four Engines of Growth
Here is where ACI stops being a commodity story and becomes a platform story. The next 24–36 months have four distinct engines:
Engine 1: Bromine volume and value ramp-up
Bromine demand is structurally healthy – flame retardants for electronics and data centres, pharmaceuticals, agrochemicals, water treatment and flow batteries. ACI is debottlenecking its plant and improving brine recovery, targeting an exit run-rate of 20,000–25,000 tonnes per annum by end-FY27 (Q1 was 4,175 tonnes). If realisations hold near ₹300/kg, every incremental 2,000 tonnes of annual sales adds roughly ₹60 crore of revenue at high incremental margins. Watch item: Chinese landed bromine prices corrected 30–40% in the three months to July 2026, so contract negotiations through the year will decide how much of the pricing sticks.
Engine 2: Bromine derivatives (Acume) scaling from breakeven
The Jhagadia plant makes PTA catalysts (5,000 TPA) and clear brine fluids (13,000 TPA), with a 10,000 TPA flame-retardant line expected in 12–18 months. Utilisation is only ~40%, so revenue can multiply without fresh capex. The business just turned EBITDA-positive; every quarter of higher utilisation and richer product mix (pharma-grade bromides) adds straight to consolidated profit.
Engine 3: India's first silicon carbide semiconductor fab (SiCSem)
This is the optionality that makes ACI unique among Indian chemical smallcaps. Through subsidiary Neun Infra, the group holds 70% of SiCSem, which is building India's first approved silicon carbide fab plus ATMP unit at Info Valley, Bhubaneswar – a ~₹2,067 crore project backed by a fiscal support agreement signed with the India Semiconductor Mission in May 2026. At full scale it is designed to produce about 60,000 SiC wafers and ~96 million power devices (MOSFETs/diodes) annually, serving EVs, solar inverters, industrial drives and 5G infrastructure. The technology edge comes from a 21% stake in UK's Clas-SiC Wafer Fab. Commissioning is targeted around FY28. If executed, this could completely re-rate the stock; until then, it consumes capital (ACI has sanctioned a ₹560 crore loan to the venture) and drags ROCE.
Engine 4: Zinc-bromide batteries (Offgrid Energy Labs)
ACI invested US$12 million for an 18.14% stake in Offgrid Energy Labs, whose proprietary ZincGel batteries use zinc-bromide chemistry for long-duration, non-flammable energy storage. Offgrid commissioned its first 10 MWh pilot line in Hook, UK in July 2026, with an eventual gigafactory planned in India. The direct synergy: ACI becomes the primary zinc-bromide supplier as this scales – converting a chemical input into a downstream growth market.
Add to this the SOP reboot (Phase-2 trials by December 2026, 9,000–10,000 tonne sales target for FY27, India being a net importer), the oilfield chemicals business moving into customer trials across five plants, and the core salt business regaining volume from Q3 – and you can see the shape of an earnings recovery in FY27–FY28.
7. Risk Factors – What Can Go Wrong
- Commodity cyclicality: Nearly 54% of current revenue is still industrial salt, and bromine prices are hostage to Chinese supply. A renewed bromine price war would hit the recovery thesis hard.
- Logistics and geopolitics: West Asia tensions, freight rates and the Gujarat road project have already cost the company real money; another quarter of slippage delays the recovery.
- Customer concentration: One customer (Sojitz) accounts for ~36% of revenue.
- Execution risk on new ventures: A ₹2,067 crore semiconductor project in a ₹6,100 crore market-cap company is a bold bet. Delays or cost overruns would stretch the balance sheet (borrowings already up to ~₹466 crore) and keep ROCE depressed.
- Rising promoter pledges – detailed earlier; needs quarterly monitoring.
- Valuation risk: At 60x+ trailing earnings, any disappointment gets punished quickly.
8. Final Verdict – Should You Buy ACI?
Option Matrix India View
ACI today is a "cheap assets, expensive stock" paradox. The core business sits on genuinely scarce resources – 240 sq km of brine fields, captive port, India's largest bromine export franchise, and the country's only natural-brine SOP unit – all of which are close to an earnings trough, with Q1 FY27 confirming the turn. On top of that sits a free option on semiconductors and energy storage that no other Indian chemical smallcap offers.
For long-term investors with 2–3 year patience and a tolerance for volatility, accumulating in the ₹470–520 band looks reasonable, with the Q3 FY27 results (salt normalisation + bromine run-rate) and SiCSem execution milestones being the key checkpoints. Short-term traders may find better risk-reward elsewhere until margins visibly expand. Position sizing should respect that this is a high-beta smallcap: it can fall 20% on a bad quarter, and rise 40% on a good one. Not a "buy and forget" stock – a "buy and monitor" stock.
9. Frequently Asked Questions (FAQs)
Q. What is the full form of ACI in the stock market?
ACI is the NSE ticker for Archean Chemical Industries Limited (BSE code: 543657), a specialty marine chemicals company producing bromine, industrial salt and sulphate of potash.
Q. What were ACI's latest quarterly results?
For Q1 FY27 (June 2026 quarter), consolidated revenue rose 11.9% YoY to a record ₹327 crore, EBITDA was ₹73 crore (up ~49% QoQ), and net profit was ₹30.4 crore – more than double the preceding quarter, though still down ~24% YoY.
Q. Who are the promoters of Archean Chemical and how much do they hold?
The promoter group (led by the founder family entities Chemikas Speciality LLP and Chemilas Speciality LLP) holds 53.43% as of June 2026. FIIs hold 11% and DIIs 24.2%.
Q. Is Archean Chemical a profitable company?
Yes. Despite a down-cycle, ACI remained profitable every year – FY26 net profit was ₹105 crore on revenue of ₹1,081 crore, and it paid a ₹2.50 per share dividend.
Q. Why is ACI building a semiconductor fab?
Through 70%-owned step-down subsidiary SiCSem, ACI is developing India's first approved silicon carbide fab and ATMP facility in Bhubaneswar (~₹2,067 crore), supported by the India Semiconductor Mission, to make power chips for EVs, renewables and industrial applications.
Q. Is ACI part of the Nifty 500 index?
No. ACI is a smallcap and is currently a constituent of the Nifty Smallcap 500 and Nifty Microcap 250 indices, along with BSE SmallCap and BSE Commodities.
Q. What is the target price for Archean Chemical shares?
Post Q1 FY27 results, leading broker targets for the stock range roughly between ₹530 and ₹670, with the Street average around ₹590–600 versus a market price of about ₹498 in late August 2026.
↑ Back to top | More such deep-dive stock analyses on Option Matrix India.
Archean Chemical Industries (ACI) Share Analysis: Earnings, Latest Results, Shareholding Pattern & the Road Ahead
Every bull market throws up companies that promise to become something entirely different from what they are today. Archean Chemical Industries Limited (ACI) is one of those fascinating bets. On paper, it is a specialty marine chemicals company making bromine, industrial salt and sulphate of potash from the brine reserves of the Rann of Kutch. Dig deeper, and you find it is quietly building India's first approved silicon carbide (SiC) semiconductor fab in Odisha, an 18% stake in a UK-based zinc-bromide battery venture, and a fast-maturing bromine derivatives business. The stock has been beaten down over the past year, but the Q1 FY27 results have started showing green shoots. Is this a multi-bagger in the making or an expensive chemical stock with too many irons in the fire? Let us break it down completely.
What's Inside This Article
1. Company Overview – What Does ACI Actually Do?
Archean Chemical Industries is a Chennai-headquartered, specialty marine chemicals manufacturer with its integrated production facility at Hajipir, on the northern edge of the Rann of Kutch brine fields in Gujarat. The facility, along with its surrounding salt fields and brine reservoirs, spans roughly 240 square kilometres – making it one of the largest single-location salt works anywhere in the world. The company owns captive port infrastructure (Jakhau jetty) and ships through Mundra and Kandla ports.
Think of ACI as a "brine refinery". Sea brine is evaporated, and from that single resource the company extracts three products:
- Bromine (the profit engine): Installed capacity of 42,500 tonnes per annum (28,500 TPA merchant + 14,000 TPA captive). ACI is the largest exporter of bromine from India and enjoys a leadership position in elemental bromine merchant sales globally. Bromine goes into flame retardants, pharma APIs, agrochemicals, water treatment, oilfield chemicals and now, energy storage.
- Industrial salt (the volume engine): A massive 75 lakh tonnes per annum capacity – and it is a 100% export-oriented business serving chlor-alkali producers in Japan, South Korea, East Asia and the Middle East.
- Sulphate of Potash (SOP – the optional kicker): 1,32,000 TPA capacity. ACI is the only manufacturer of natural sea-brine-based SOP in India, a country that otherwise imports this chloride-free fertiliser.
Beyond these three legacy lines, ACI has layered on four new businesses: bromine derivatives (Acume Chemicals, Jhagadia, Gujarat), oilfield/mud chemicals (Idealis Mudchemie, acquired out of an NCLT auction for about ₹77 crore), silicon carbide power semiconductors (SiCSem, Odisha), and zinc-bromide batteries (strategic stake in Offgrid Energy Labs, UK).
2. The Journey So Far – Past Performance
ACI's story has three clear chapters. Chapter one (2013–2022): build-out. Salt operations began in 2013, bromine in 2014, SOP in 2015. Japanese trading house Sojitz came in as a strategic investor in 2011, and by FY22 the company was generating ₹1,130 crore of revenue.
Chapter two (FY23–FY24): the golden era. Global bromine prices spiked, and ACI printed stunning numbers – FY23 revenue of ₹1,441 crore with a 44% operating margin and ₹383 crore net profit. The company went public in November 2022 at ₹407 per share (a ₹1,462 crore IPO), used ₹805 crore of fresh money to become almost debt-free, and listed at around ₹458.
Chapter three (FY25–FY26): the reality check. Bromine prices corrected sharply on Chinese oversupply and soft demand, industrial salt pricing weakened, a cyclone wiped out ~4.7 lakh tonnes of salt inventory (a ₹40 crore one-off loss in FY25), and the new ventures were still bleeding money. Result: PAT fell from ₹383 crore in FY23 to just ₹105 crore in FY26. The stock, which touched ₹727 in August 2025, slid to a 52-week low of ₹483 by December 2025 and has broadly remained in the ₹490–580 band since.
| Consolidated (₹ Cr) | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue from operations | 1,441 | 1,330 | 1,041 | 1,081 |
| Operating profit (EBITDA) | 634 | 463 | 315 | 239 |
| EBITDA margin | 44% | 35% | 30% | 22% |
| Net profit (PAT) | 383 | 319 | 162 | 105 |
| Earnings per share (₹) | 31.1 | 25.9 | 13.1 | 8.66 |
| ROCE | ~45% | ~25% | ~13% | ~7.4% |
That table tells you everything about why the stock de-rated. Three-year profit CAGR is deeply negative, and return ratios have compressed from spectacular to ordinary as capex on new ventures rose and core margins cooled. Balance-sheet-wise, the company still carries healthy reserves (₹1,910 crore as of March 2026), but borrowings have climbed back to about ₹466 crore to fund the semiconductor and battery bets. Dividend has been maintained – ₹2.50 per share for FY26 (roughly 29% payout, ~0.5% yield at current price).
3. Latest Quarterly Result – Q1 FY27 (June 2026 Quarter)
Declared on 30 July 2026, this was arguably ACI's most important result in six quarters – the first clear evidence that the down-cycle is bottoming out.
| Consolidated (₹ Cr) | Q1 FY27 (Jun '26) | Q4 FY26 (Mar '26) | Q1 FY26 (Jun '25) | YoY Change |
|---|---|---|---|---|
| Revenue | 327 | 301 | 292 | +11.9% |
| EBITDA | 73 | 49 | 86 | –15.6% |
| EBITDA margin | ~21% | ~15% | ~27% | –600 bps |
| Net profit (PAT) | 30.4 | 13.4 | 40.2 | –23.7% |
| EPS (₹) | 2.48 | 1.13 | 3.25 | down |
Read the headline and the direction together: revenue hit a record quarterly high of ₹327 crore (highest-ever quarterly sales for the company), and profit more than doubled sequentially from the miserable March quarter. But versus last year, profitability is still lower. Here is what actually happened inside the business:
- Bromine roared back: Segment revenue jumped 58% YoY to ₹133 crore on volumes of 4,175 tonnes (a five-quarter high) and realisations up ~50% YoY to roughly ₹300 per kg. Demand from flame retardants, oilfield chemicals and energy storage stayed firm, and management expects realisations to hold near this level.
- Industrial salt struggled: Revenue fell 12% YoY to ₹171 crore as volumes dropped to 9.82 lakh tonnes. The culprits were purely operational – Gujarat highway construction lengthened truck routes by 50–100% (the Hajipir–Jakhau haul nearly doubled to 500+ km), diesel prices ran ~60% higher YoY during April–June, sea freight rose 30–35% due to the West Asia conflict, and a key Middle East salt customer stayed on hold. Crucially, salt pricing has stabilised after falling through FY26.
- Bromine derivatives turned EBITDA-positive for the first time: Acume Chemicals grew revenue 28% YoY to ~₹30 crore and posted positive EBITDA of ₹1.9 crore (versus a ₹2.7 crore loss a year ago) on ~40% capacity utilisation. Pharma-grade variants and organic bromides are leading the mix.
- SOP is coming back to life: Revenue of ₹11.3 crore in the quarter – against just ₹3.5 crore in ALL of FY26 – on 1,952 tonnes sold at ~₹58,000/tonne. The re-engineered manufacturing process cleared Phase-1 trials in June 2026; Phase-2 trials are due by December 2026.
- New-age ventures in investment mode: The semiconductor venture (Neun/SiCSem) and oilfield chemicals arm (Idealis) together remain loss-making at the EBITDA level, dragging consolidated profit about ₹10 crore below standalone profit.
4. Shareholding Pattern – Who Owns ACI?
The shareholding of ACI is actually one of its better features: a stable promoter, rising foreign ownership, and strong domestic institutional backing.
| Shareholder Category | Mar 2024 | Mar 2025 | Jun 2026 |
|---|---|---|---|
| Promoters & Promoter Group | 53.46% | 53.44% | 53.43% |
| Foreign Institutional Investors (FIIs) | 5.86% | 10.93% | 11.00% |
| Domestic Institutional Investors (DIIs) | 27.13% | 23.17% | 24.18% |
| – of which Mutual Funds | – | – | 16.15% |
| Public & Others | 13.54% | 12.44% | 11.40% |
Institutions (FIIs + DIIs) together hold roughly 35% of the company – a strong vote of professional confidence for a smallcap. FII holding has almost doubled since FY24. Retail participation, interestingly, has thinned – the shareholder count has come down from about 1.07 lakh in March 2024 to around 67,000 now, suggesting weak hands have exited the stock during the down-cycle.
5. Present – Where the Stock Stands Right Now
As of late August 2026, ACI trades around ₹498, valuing the company at roughly ₹6,100 crore. The stock is down about 24–26% over the past year, has a 52-week range of ₹483–727.6, and trades at a trailing P/E of about 63x with a price-to-book of ~3.2x. On current earnings, that is expensive – no two ways about it. The bull case rests entirely on the earnings recovery that Q1 FY27 has begun to signal.
| Valuation Snapshot (Aug 2026) | ACI | Pidilite | Navin Fluorine | Deepak Nitrite | Aarti Inds. |
|---|---|---|---|---|---|
| P/E (trailing) | ~63x | ~63x | ~53x | ~30x | ~37x |
| ROCE | 7.4% | 31% | 21% | 11% | 7% |
The Street remains cautiously constructive. Post the Q1 print, a large domestic broker reiterated a Buy with a target of ₹640 (valuing the company at 16x FY28E EV/EBITDA), while flagging SiCSem execution as the key re-rating catalyst. Broad analyst consensus targets cluster around the ₹590–600 mark – implying roughly 20% upside from current levels, though estimates vary widely because FY27–28 earnings are unusually hard to model. It is also worth noting that ACI is a small-cap index constituent (part of the Nifty Smallcap 500 and Nifty Microcap 250 baskets) – so index flows matter, and the stock is not yet in the big league of index heavyweights.
6. Future – Four Engines of Growth
Here is where ACI stops being a commodity story and becomes a platform story. The next 24–36 months have four distinct engines:
Engine 1: Bromine volume and value ramp-up
Bromine demand is structurally healthy – flame retardants for electronics and data centres, pharmaceuticals, agrochemicals, water treatment and flow batteries. ACI is debottlenecking its plant and improving brine recovery, targeting an exit run-rate of 20,000–25,000 tonnes per annum by end-FY27 (Q1 was 4,175 tonnes). If realisations hold near ₹300/kg, every incremental 2,000 tonnes of annual sales adds roughly ₹60 crore of revenue at high incremental margins. Watch item: Chinese landed bromine prices corrected 30–40% in the three months to July 2026, so contract negotiations through the year will decide how much of the pricing sticks.
Engine 2: Bromine derivatives (Acume) scaling from breakeven
The Jhagadia plant makes PTA catalysts (5,000 TPA) and clear brine fluids (13,000 TPA), with a 10,000 TPA flame-retardant line expected in 12–18 months. Utilisation is only ~40%, so revenue can multiply without fresh capex. The business just turned EBITDA-positive; every quarter of higher utilisation and richer product mix (pharma-grade bromides) adds straight to consolidated profit.
Engine 3: India's first silicon carbide semiconductor fab (SiCSem)
This is the optionality that makes ACI unique among Indian chemical smallcaps. Through subsidiary Neun Infra, the group holds 70% of SiCSem, which is building India's first approved silicon carbide fab plus ATMP unit at Info Valley, Bhubaneswar – a ~₹2,067 crore project backed by a fiscal support agreement signed with the India Semiconductor Mission in May 2026. At full scale it is designed to produce about 60,000 SiC wafers and ~96 million power devices (MOSFETs/diodes) annually, serving EVs, solar inverters, industrial drives and 5G infrastructure. The technology edge comes from a 21% stake in UK's Clas-SiC Wafer Fab. Commissioning is targeted around FY28. If executed, this could completely re-rate the stock; until then, it consumes capital (ACI has sanctioned a ₹560 crore loan to the venture) and drags ROCE.
Engine 4: Zinc-bromide batteries (Offgrid Energy Labs)
ACI invested US$12 million for an 18.14% stake in Offgrid Energy Labs, whose proprietary ZincGel batteries use zinc-bromide chemistry for long-duration, non-flammable energy storage. Offgrid commissioned its first 10 MWh pilot line in Hook, UK in July 2026, with an eventual gigafactory planned in India. The direct synergy: ACI becomes the primary zinc-bromide supplier as this scales – converting a chemical input into a downstream growth market.
Add to this the SOP reboot (Phase-2 trials by December 2026, 9,000–10,000 tonne sales target for FY27, India being a net importer), the oilfield chemicals business moving into customer trials across five plants, and the core salt business regaining volume from Q3 – and you can see the shape of an earnings recovery in FY27–FY28.
7. Risk Factors – What Can Go Wrong
- Commodity cyclicality: Nearly 54% of current revenue is still industrial salt, and bromine prices are hostage to Chinese supply. A renewed bromine price war would hit the recovery thesis hard.
- Logistics and geopolitics: West Asia tensions, freight rates and the Gujarat road project have already cost the company real money; another quarter of slippage delays the recovery.
- Customer concentration: One customer (Sojitz) accounts for ~36% of revenue.
- Execution risk on new ventures: A ₹2,067 crore semiconductor project in a ₹6,100 crore market-cap company is a bold bet. Delays or cost overruns would stretch the balance sheet (borrowings already up to ~₹466 crore) and keep ROCE depressed.
- Rising promoter pledges – detailed earlier; needs quarterly monitoring.
- Valuation risk: At 60x+ trailing earnings, any disappointment gets punished quickly.
8. Final Verdict – Should You Buy ACI?
Option Matrix India View
ACI today is a "cheap assets, expensive stock" paradox. The core business sits on genuinely scarce resources – 240 sq km of brine fields, captive port, India's largest bromine export franchise, and the country's only natural-brine SOP unit – all of which are close to an earnings trough, with Q1 FY27 confirming the turn. On top of that sits a free option on semiconductors and energy storage that no other Indian chemical smallcap offers.
For long-term investors with 2–3 year patience and a tolerance for volatility, accumulating in the ₹470–520 band looks reasonable, with the Q3 FY27 results (salt normalisation + bromine run-rate) and SiCSem execution milestones being the key checkpoints. Short-term traders may find better risk-reward elsewhere until margins visibly expand. Position sizing should respect that this is a high-beta smallcap: it can fall 20% on a bad quarter, and rise 40% on a good one. Not a "buy and forget" stock – a "buy and monitor" stock.
9. Frequently Asked Questions (FAQs)
Q. What is the full form of ACI in the stock market?
ACI is the NSE ticker for Archean Chemical Industries Limited (BSE code: 543657), a specialty marine chemicals company producing bromine, industrial salt and sulphate of potash.
Q. What were ACI's latest quarterly results?
For Q1 FY27 (June 2026 quarter), consolidated revenue rose 11.9% YoY to a record ₹327 crore, EBITDA was ₹73 crore (up ~49% QoQ), and net profit was ₹30.4 crore – more than double the preceding quarter, though still down ~24% YoY.
Q. Who are the promoters of Archean Chemical and how much do they hold?
The promoter group (led by the founder family entities Chemikas Speciality LLP and Chemilas Speciality LLP) holds 53.43% as of June 2026. FIIs hold 11% and DIIs 24.2%.
Q. Is Archean Chemical a profitable company?
Yes. Despite a down-cycle, ACI remained profitable every year – FY26 net profit was ₹105 crore on revenue of ₹1,081 crore, and it paid a ₹2.50 per share dividend.
Q. Why is ACI building a semiconductor fab?
Through 70%-owned step-down subsidiary SiCSem, ACI is developing India's first approved silicon carbide fab and ATMP facility in Bhubaneswar (~₹2,067 crore), supported by the India Semiconductor Mission, to make power chips for EVs, renewables and industrial applications.
Q. Is ACI part of the Nifty 500 index?
No. ACI is a smallcap and is currently a constituent of the Nifty Smallcap 500 and Nifty Microcap 250 indices, along with BSE SmallCap and BSE Commodities.
Q. What is the target price for Archean Chemical shares?
Post Q1 FY27 results, leading broker targets for the stock range roughly between ₹530 and ₹670, with the Street average around ₹590–600 versus a market price of about ₹498 in late August 2026.
↑ Back to top | More such deep-dive stock analyses on Option Matrix India.